At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
LY2189265 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating LY2189265 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 145 participants across 6 sites.
Detailed Summary
The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionDec 2010
TodayJul 2026
First PostedOct 23, 2009
Enrollment StartOct 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.7 years ago
Interventions
LY2189265drug
Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Placebodrug
Administered by SC injection, QW for 12 weeks.